This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tatsumi, T. Articles by Storkus, W. J. Search for Related Content PubMed PubMed Citation Articles by Tatsumi, T. Articles by Storkus, W. J.

Intratumoral Delivery of Dendritic Cells Engineered to Secrete Both Interleukin (IL)-12 and IL-18 Effectively Treats Local and Distant Disease in Association with Broadly Reactive Tc1-type Immunity¹

Departments of Surgery [T. T., A. G., W. J. S.], Immunology [J. H., W. J. S.], Biostatistics [W. E. G.], Molecular Genetics and Biochemistry [A. G., P. D. R.], Pathology [N. L. V., S. M. A., S. C. W.], and Neurosurgery [H. O.], University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute [A. G., P. D. R., N. L. V., W. J. S.], and University of Pittsburgh Molecular Medicine Institute [A. G., P. D. R., W. J. S.], Pittsburgh, Pennsylvania 15213

Dendritic cells (DCs) were adenovirally engineered to constitutively and durably secrete the potent Th1-biasing cytokines interleukin (IL)-12 (AdIL12DC) and/or IL-18 (AdIL18DC) and evaluated for their ability to promote therapeutic antitumor immunity in murine sarcoma models. Injection of either AdIL12DC or AdIL18DC into day 7 CMS4 or MethA tumors resulted in tumor rejection or slowed tumor growth when compared with control cohorts. Importantly, intratumoral injection with DCs engineered to secrete both IL-12 and IL-18 (AdIL12/IL18DC) resulted in complete and the most acute rejection of any treatment group analyzed. This strategy was also effective in promoting the regression of contralateral, untreated tumors. Both CD4+ and CD8+ T cells were required for tumor rejection. CD8+ splenic T cells from mice treated with AdIL12/IL18DC produced the highest levels of IFN- in response to tumor rechallenge in vitro and displayed the broadest repertoire of Tc1-type reactivity to acid-eluted, tumor-derived peptides among all treatment cohorts. This apparent enhancement in cross-presentation of tumor-associated epitopes in vivo may result from the increased capacity of engineered DCs to kill tumor cells, survive tumor-induced apoptosis, and present immunogenic MHC/tumor peptide complexes to T cells after intratumoral injection. In support of this hypothesis, cytokine gene-engineered DCs expressed higher levels of MHC and costimulatory molecules, as well as Fas ligand and membrane-bound tumor necrosis factor , with the latter markers associated with elevated tumoricidal activity in vitro. Cytokine gene-engineered DCs appeared to have a survival advantage in situ when injected into tumor lesions, to be found in approximation with regions of tumor apoptosis, and to have the capacity to ingest apoptotic tumor bodies. These results support the ability of combined cytokine gene transfer to enhance multiple effector functions mediated by intralesionally injected DCs that may concertedly promote cross-priming and the accelerated immune-mediated rejection of tumors.

This article has been cited by other articles:

				N. Ohta, Y. Ohashi, and Y. Fujino Ketamine Inhibits Maturation of Bone Marrow-Derived Dendritic Cells and Priming of the Th1-Type Immune Response Anesth. Analg., September 1, 2009; 109(3): 793 - 800. [Abstract] [Full Text] [PDF]

				A. Khatri, Y. Husaini, K. Ow, J. Chapman, and P. J. Russell Cytosine Deaminase-Uracil Phosphoribosyltransferase and Interleukin (IL)-12 and IL-18: A Multimodal Anticancer Interface Marked by Specific Modulation in Serum Cytokines Clin. Cancer Res., April 1, 2009; 15(7): 2323 - 2334. [Abstract] [Full Text] [PDF]

				H. Komita, X. Zhao, J. L. Taylor, L. J. Sparvero, A. A. Amoscato, S. Alber, S. C. Watkins, A. D. Pardee, A. K. Wesa, and W. J. Storkus CD8+ T-Cell Responses against Hemoglobin-{beta} Prevent Solid Tumor Growth Cancer Res., October 1, 2008; 68(19): 8076 - 8084. [Abstract] [Full Text] [PDF]

				H. Wei, H. Wang, B. Lu, B. Li, S. Hou, W. Qian, K. Fan, J. Dai, J. Zhao, and Y. Guo Cancer Immunotherapy Using In vitro Genetically Modified Targeted Dendritic Cells Cancer Res., May 15, 2008; 68(10): 3854 - 3862. [Abstract] [Full Text] [PDF]

				M. Del Vecchio, E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini Interleukin-12: Biological Properties and Clinical Application Clin. Cancer Res., August 15, 2007; 13(16): 4677 - 4685. [Abstract] [Full Text] [PDF]

				A. E. M. Dirkx, M. G. A. oude Egbrink, J. Wagstaff, and A. W. Griffioen Monocyte/macrophage infiltration in tumors: modulators of angiogenesis J. Leukoc. Biol., December 1, 2006; 80(6): 1183 - 1196. [Abstract] [Full Text] [PDF]

				A. Berhanu, J. Huang, S. M. Alber, S. C. Watkins, and W. J. Storkus Combinational FLt3 Ligand and Granulocyte Macrophage Colony-Stimulating Factor Treatment Promotes Enhanced Tumor Infiltration by Dendritic Cells and Antitumor CD8+ T-Cell Cross-priming but Is Ineffective as a Therapy. Cancer Res., May 1, 2006; 66(9): 4895 - 4903. [Abstract] [Full Text] [PDF]

				M. Guan, J. R. Rodriguez-Madoz, P. Alzuguren, C. Gomar, M. G. Kramer, S. Kochanek, J. Prieto, C. Smerdou, and C. Qian Increased Efficacy and Safety in the Treatment of Experimental Liver Cancer with a Novel Adenovirus-Alphavirus Hybrid Vector Cancer Res., February 1, 2006; 66(3): 1620 - 1629. [Abstract] [Full Text] [PDF]

				N. Kuwashima, F. Nishimura, J. Eguchi, H. Sato, M. Hatano, T. Tsugawa, T. Sakaida, J. E. Dusak, W. K. Fellows-Mayle, G. D. Papworth, et al. Delivery of Dendritic Cells Engineered to Secrete IFN-{alpha} into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways J. Immunol., August 15, 2005; 175(4): 2730 - 2740. [Abstract] [Full Text] [PDF]

				P. L. Triozzi, K. O. Allen, R. R. Carlisle, M. Craig, A. F. LoBuglio, and R. M. Conry Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma Clin. Cancer Res., June 1, 2005; 11(11): 4168 - 4175. [Abstract] [Full Text] [PDF]

				Q. Li, A. L. Carr, E. J. Donald, J. J. Skitzki, R. Okuyama, L. M. Stoolman, and A. E. Chang Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern Cancer Res., February 1, 2005; 65(3): 1063 - 1070. [Abstract] [Full Text] [PDF]

				H. Okada, T. Tsugawa, H. Sato, N. Kuwashima, A. Gambotto, K. Okada, J. E. Dusak, W. K. Fellows-Mayle, G. D. Papworth, S. C. Watkins, et al. Delivery of Interferon-{alpha} Transfected Dendritic Cells into Central Nervous System Tumors Enhances the Antitumor Efficacy of Peripheral Peptide-Based Vaccines Cancer Res., August 15, 2004; 64(16): 5830 - 5838. [Abstract] [Full Text] [PDF]

				C. Perrotta, S. Falcone, A. Capobianco, A. Camporeale, C. Sciorati, C. D. Palma, A. Pisconti, P. Rovere-Querini, M. Bellone, A. A. Manfredi, et al. Nitric Oxide Confers Therapeutic Activity to Dendritic Cells in a Mouse Model of Melanoma Cancer Res., June 1, 2004; 64(11): 3767 - 3771. [Abstract] [Full Text] [PDF]